Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q460N5
UPID:
PAR14_HUMAN
Alternative names:
ADP-ribosyltransferase diphtheria toxin-like 8; B aggressive lymphoma protein 2; Poly [ADP-ribose] polymerase 14
Alternative UPACC:
Q460N5; B4E2H0; Q460N4; Q8J027; Q9H9X9; Q9NV60; Q9ULF2
Background:
Protein mono-ADP-ribosyltransferase PARP14, also known as ADP-ribosyltransferase diphtheria toxin-like 8, B aggressive lymphoma protein 2, and Poly [ADP-ribose] polymerase 14, plays a crucial role in cellular processes. It mediates mono-ADP-ribosylation of glutamate residues on target proteins, influencing various signaling pathways. Unlike PARP1 and PARP2, PARP14 does not mediate poly-ADP-ribosylation. It specifically modifies STAT1 and STAT6, affecting their phosphorylation and thereby regulating cytokine production and transcription in response to immune stimuli.
Therapeutic significance:
Understanding the role of Protein mono-ADP-ribosyltransferase PARP14 could open doors to potential therapeutic strategies. Its involvement in modulating immune responses and gene expression highlights its potential as a target in treating inflammatory diseases and immune-related disorders.